10x Genomics, Inc. Class A Common Stock Earnings Dividend

10x Genomics, Inc. Class A Common Stock’s revenue fell -12.65% since last year same period to $151.04Mn in the Q2 2026. On a quarterly growth basis, 10x Genomics, Inc. Class A Common Stock has generated 0.13% jump in its revenue since last 3-months.

10x Genomics, Inc. Class A Common Stock’s net profit fell -151.92% since last year same period to $-17.93Mn in the Q2 2026. On a quarterly growth basis, 10x Genomics, Inc. Class A Common Stock has generated -33.12% fall in its net profits since last 3-months.

10x Genomics, Inc. Class A Common Stock’s net profit margin fell -159.43% since last year same period to -11.87% in the Q2 2026. On a quarterly growth basis, 10x Genomics, Inc. Class A Common Stock has generated -32.95% fall in its net profit margins since last 3-months.

10x Genomics, Inc. Class A Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a -283.33% fall from last quarter’s estimates.

10x Genomics, Inc. Class A Common Stock’s earning per share (EPS) estimates for the current year stand at -0.23.

10x Genomics, Inc. Class A Common Stock’s earning per share (EPS) fell -150% since last year same period to -0.14 in the Q2 2026. This indicates that the 10x Genomics, Inc. Class A Common Stock has generated -150% annual rate of fall in its earning per share (EPS) in the last 4 quarters.